Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

206 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function.
Kielgast U, Krarup T, Holst JJ, Madsbad S. Kielgast U, et al. Diabetes Care. 2011 Jul;34(7):1463-8. doi: 10.2337/dc11-0096. Epub 2011 May 18. Diabetes Care. 2011. PMID: 21593296 Free PMC article. Clinical Trial.
Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials.
Madsbad S, Krarup T, Deacon CF, Holst JJ. Madsbad S, et al. Curr Opin Clin Nutr Metab Care. 2008 Jul;11(4):491-9. doi: 10.1097/MCO.0b013e328302f414. Curr Opin Clin Nutr Metab Care. 2008. PMID: 18542012 Review.
GLP-1: physiological effects and potential therapeutic applications.
Aaboe K, Krarup T, Madsbad S, Holst JJ. Aaboe K, et al. Diabetes Obes Metab. 2008 Nov;10(11):994-1003. doi: 10.1111/j.1463-1326.2008.00853.x. Epub 2008 Apr 22. Diabetes Obes Metab. 2008. PMID: 18435775 Review.
Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes.
Vilsbøll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courrèges JP, Verhoeven R, Bugánová I, Madsbad S. Vilsbøll T, et al. Diabetes Care. 2007 Jun;30(6):1608-10. doi: 10.2337/dc06-2593. Epub 2007 Mar 19. Diabetes Care. 2007. PMID: 17372153 Clinical Trial. No abstract available.
Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?
Knop FK, Vilsbøll T, Højberg PV, Larsen S, Madsbad S, Vølund A, Holst JJ, Krarup T. Knop FK, et al. Diabetes. 2007 Aug;56(8):1951-9. doi: 10.2337/db07-0100. Epub 2007 May 18. Diabetes. 2007. PMID: 17513701
Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes.
Christensen M, Knop FK, Vilsbøll T, Aaboe K, Holst JJ, Madsbad S, Krarup T. Christensen M, et al. Regul Pept. 2010 Aug 9;163(1-3):96-101. doi: 10.1016/j.regpep.2010.05.004. Epub 2010 May 24. Regul Pept. 2010. PMID: 20580750
KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes.
Aaboe K, Knop FK, Vilsboll T, Vølund A, Simonsen U, Deacon CF, Madsbad S, Holst JJ, Krarup T. Aaboe K, et al. J Clin Endocrinol Metab. 2009 Feb;94(2):603-8. doi: 10.1210/jc.2008-1731. Epub 2008 Dec 2. J Clin Endocrinol Metab. 2009. PMID: 19050053 Clinical Trial.
Glucagon-like peptide-1, glucose homeostasis and diabetes.
Holst JJ, Deacon CF, Vilsbøll T, Krarup T, Madsbad S. Holst JJ, et al. Trends Mol Med. 2008 Apr;14(4):161-8. doi: 10.1016/j.molmed.2008.01.003. Epub 2008 Mar 18. Trends Mol Med. 2008. PMID: 18353723 Review.
206 results
Jump to page
Feedback